LIBTAYO is the first and only medicine approved by the Food and Drug Administration (FDA) to treat cutaneous squamous cell carcinoma (CSCC) that has spread or cannot be cured by surgery or radiation.
Immunotherapy can help the body’s immune system fight cancer. LIBTAYO is a type of immunotherapy treatment called a programmed death receptor-1 (PD-1) inhibitor. LIBTAYO is not chemotherapy or radiation therapy.
LIBTAYO may be right for people with CSCC that:
has spread (metastasized)OR
cured by surgery or radiation
Ask your healthcare provider whether LIBTAYO is a treatment option you should consider.